Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks

PLoS One. 2013;8(3):e58234. doi: 10.1371/journal.pone.0058234. Epub 2013 Mar 8.


Here we present mumps virus specific antibody levels in a large cross-sectional population-based serosurveillance study performed in the Netherlands in 2006/2007 (n = 7900). Results were compared with a similar study (1995/1996) and discussed in the light of recent outbreaks. Mumps antibodies were tested using a fluorescent bead-based multiplex immunoassay. Overall seroprevalence was 90.9% with higher levels in the naturally infected cohorts compared with vaccinated cohorts. Mumps virus vaccinations at 14 months and 9 years resulted in an increased seroprevalence and antibody concentration. The second vaccination seemed to be important in acquiring stable mumps antibody levels in the long term. In conclusion, the Dutch population is well protected against mumps virus infection. However, we identified specific age- and population groups at increased risk of mumps infection. Indeed, in 2007/2008 an outbreak has occurred in the low vaccination coverage groups emphasizing the predictive value of serosurveillance studies.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Child
  • Child, Preschool
  • Disease Outbreaks*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Mumps / blood
  • Mumps / epidemiology*
  • Mumps / prevention & control*
  • Mumps Vaccine / administration & dosage*
  • Netherlands / epidemiology
  • Retrospective Studies
  • Seroepidemiologic Studies
  • Vaccination*


  • Antibodies, Viral
  • Mumps Vaccine

Grants and funding

The authors have no support or funding to report.